Pterygopalatine Fossa Block in Aneurysmal Subarachnoid Hemorrhage

Last updated: August 21, 2024
Sponsor: University of Texas Southwestern Medical Center
Overall Status: Completed

Phase

1

Condition

Stroke

Hemorrhage

Treatment

Bupivacaine 0.25% Injectable Solution

Ptergyopalatine Fossa Block

Clinical Study ID

NCT05925478
STU-2023-0176
  • Ages > 18
  • All Genders

Study Summary

Aneurysmal subarachnoid hemorrhage (aSAH) can cause a severe headache (HA) that is famously treatment-resistant. Current pain regimens are too reliant on opioids, which results in long-term opioid dependence and can obfuscate the neurological examination, which is critical to detect vasospasm and delayed cerebral ischemia. This study will gather the initial evidence of whether the pterygopalatine fossa (PPF) regional anesthesia nerve block can treat aSAH-related HA and reduce opioid consumption in patients with aSAH.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aneurysmal subarachnoid hemorrhage with secured aneurysm

  • Age greater than or equal to 18 years

  • Able to communicate pain level

Exclusion

Exclusion Criteria:

  • Documented allergy to local anesthetics (e.g. bupivicaine)

  • Patients with unsecured aneurysms

  • Patients who are unable to communicate pain level (e.g. sedation/mechanicalventilation/delirium, etc)

  • Medical treatment for vasospasm including blood pressure/inotropic augmentation

  • Angiographic treatment for vasospasm within 48 hours

Study Design

Total Participants: 2
Treatment Group(s): 2
Primary Treatment: Bupivacaine 0.25% Injectable Solution
Phase: 1
Study Start date:
November 06, 2023
Estimated Completion Date:
August 20, 2024

Connect with a study center

  • UT Southwestern

    Dallas, Texas 75235
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.